Inclusion Criteria (Key factors listed):

          -  Eastern Cooperative Oncology Group Performance Status of ≤2.

          -  Confirmed malignancy with relapsed/refractory disease after ≥2 lines of standard
             systemic therapy including prior BTK inhibitor therapy having CLL, LPL/WM, MCL or MZL
             and for DLBCL-ABC and FL, after ≥2 lines of standard systemic therapy (Phase 1b). For
             Phase 2, CLL/SLL patients with confirmed malignancy with relapsed/refractory disease
             after ≥1 line of standard systemic therapy including prior BTK inhibitor therapy

          -  Presence of measurable disease through various assessments depending on specific
             cancer type.

          -  Current medical need for therapy of the B-lymphoid malignancy.

        Exclusion Criteria (Key factors listed):

          -  Active central nervous system involvement.

          -  History of second primary malignancy that has progressed or required systemic
             treatment in the past 2 years. Exceptions include: local cancers of the skin, cervix
             or breast cancers, non-invasive bladder cancer, hormone sensitive prostate cancer with
             stable PSA ≥3 months, and other localized solid tumors in situ/other low risk cancers.

          -  Significant cardiovascular disease or electrocardiogram (ECG) abnormalities

          -  Ongoing risk for bleeding due to bleeding diathesis, platelet function disorder,
             uncontrolled peptic ulcer disease, oral anticoagulation medications.

          -  Evidence of uncontrolled systemic bacterial, fungal or viral infections at the start
             of drug therapy.

          -  Demonstrated intolerance to BTK inhibitor as shown by discontinuation due to adverse
             effects.

          -  Use of a moderate or strong inhibitor or inducer of CYP3A4 within 7 days prior to
             start of study therapy (e.g., some antibiotics, antifungals, anticonvulsants,
             grapefruit).